The public issue is entirely an offer-for-sale (OFS) of up to 21.7 million shares by the promoters and other shareholders to the tune of around ₹1,800 crore, said bankers. The company operates under the “Blue Jet” brand offering niche products targeted at innovator pharmaceutical companies and multinational generic pharmaceutical companies.
10 stks that got upgrades & downgrades from MOSL post Q4 results
As all major companies have already announced their Q4 results, brokerage firm Motilal Oswal has upgraded and downgraded the estimated FY24 earnings of several stocks.
June 3, 2023